stockrowGain Therapeutics, Inc.
GANX Healthcare Biotechnology
Gain Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $55,200.00, down 60.6% from fiscal 2022.
- EPS
- +42.1%
- Free cash flow
- +8.22%
- Total debt
- −23.9%
Quarter to June 2026, against a year earlier
Follow GANX
Alert me
Gain Therapeutics, Inc. (GANX) Altman Z-score
Gain Therapeutics, Inc.'s Altman Z-score for fiscal 2023 is −1.79, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2023 | −1.79 | (3.26) |
| FY2022 | 1.48 | (6.13) |
| FY2021 | 7.61 | — |
How fiscal 2023’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.69 | — | 0.83 | |
| Retained earnings / total assets | (2.07) | — | −2.90 | |
| EBIT / total assets | (1.20) | — | −3.95 | |
| Market value of equity / total liabilities | 7.04 | — | 4.23 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | −1.79 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −8.07 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ATHE Alterity Therapeutics Limited - Sponsored ADR compare | 2.2× |
| GANX Gain Therapeutics, Inc. | −1.8× |
| HYPD Hyperion DeFi, Inc. compare | −8.4× |
| ATNM Actinium Pharmaceuticals, Inc. compare | −11.8× |
| SER Serina Therapeutics, Inc. compare | −22.1× |
| SGMOQ Sangamo Therapeutics, Inc. compare | −43.3× |
| BMEA Biomea Fusion, Inc. compare | — |
| LONA LeonaBio, Inc. compare | — |
| DWTX Dogwood Therapeutics, Inc compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets